Ipsen teams up for cabozantinib combo study in lung and prostate cancer [Seeking Alpha]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Seeking Alpha
HealthcareIpsen teams up for cabozantinib combo study in lung and prostate cancerJul. 2, 2020 6:46 AM ET|Ipsen S.A. (IPSEY)Mamta MayaniIpsen (OTCPK:IPSEYjoinEXELOTCQX:RHHBYCONTACT-01CONTACT-02CONTACT-01 is evaluating the safety and efficacy of Exelixis' cabozantinib (cabometyx) in combination with Roche's atezolizumab (tecentriq) in patients with metastatic non-small cell lung cancer.CONTACT-02 is evaluating the safety and efficacy of cabozantinib in combination with atezolizumab versus a second novel hormonal therapy in men with metastatic castration-resistant prostate cancer.Under this agreement, following its decision to opt-in to pivotal studies exploring cabozantinib in new potential indications, Ipsen gains access to the results of those studies, which if positive, may support potential future regulatory submissions in its territory.Ipsen has an exclusive agreement with Exelixis for the further development and commercialization of cabozantinib outside U.S. and Japan.Click to s
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in MayBusiness Wire
- Exelixis (EXEL) International Revenue Performance Explored [Yahoo! Finance]Yahoo! Finance
- Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.MarketBeat
- Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Exelixis: With Patent Litigation Decision Due Soon, There Are Options [Seeking Alpha]Seeking Alpha
EXEL
Earnings
- 4/30/24 - Miss
EXEL
Sec Filings
- 5/10/24 - Form 8-K
- 5/8/24 - Form SC
- 5/7/24 - Form 144
- EXEL's page on the SEC website